JP2025514382A - Ｒｏｃｋ２の阻害剤 - Google Patents

Ｒｏｃｋ２の阻害剤 Download PDF

Info

Publication number
JP2025514382A
JP2025514382A JP2024563854A JP2024563854A JP2025514382A JP 2025514382 A JP2025514382 A JP 2025514382A JP 2024563854 A JP2024563854 A JP 2024563854A JP 2024563854 A JP2024563854 A JP 2024563854A JP 2025514382 A JP2025514382 A JP 2025514382A
Authority
JP
Japan
Prior art keywords
alkyl
group
alkynyl
alkenyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563854A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025514382A5 (enExample
Inventor
ディー．ワクサル サミュエル
ザニン－ジョロフ アレクサンドラ
カクコブスキー ジョージー
ソルッチ マグダレナ
イェルジェチャク アンナ
クルバニャ マルチン
ドマガワ ドミニク
Original Assignee
グラビトン バイオサイエンス べスローテン フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラビトン バイオサイエンス べスローテン フェンノートシャップ filed Critical グラビトン バイオサイエンス べスローテン フェンノートシャップ
Publication of JP2025514382A publication Critical patent/JP2025514382A/ja
Publication of JP2025514382A5 publication Critical patent/JP2025514382A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024563854A 2022-04-29 2023-04-29 Ｒｏｃｋ２の阻害剤 Pending JP2025514382A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263336667P 2022-04-29 2022-04-29
US63/336,667 2022-04-29
PCT/IB2023/054494 WO2023209692A1 (en) 2022-04-29 2023-04-29 Inhibitors of rock2

Publications (2)

Publication Number Publication Date
JP2025514382A true JP2025514382A (ja) 2025-05-02
JP2025514382A5 JP2025514382A5 (enExample) 2026-05-11

Family

ID=86604437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563854A Pending JP2025514382A (ja) 2022-04-29 2023-04-29 Ｒｏｃｋ２の阻害剤

Country Status (9)

Country Link
US (1) US20250289807A1 (enExample)
EP (1) EP4514466A1 (enExample)
JP (1) JP2025514382A (enExample)
KR (1) KR20250019030A (enExample)
CN (1) CN119604496A (enExample)
AU (1) AU2023262720A1 (enExample)
CA (1) CA3250707A1 (enExample)
IL (1) IL316616A (enExample)
WO (1) WO2023209692A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026502949A (ja) 2022-12-30 2026-01-27 アヴィセンナ バイオサイエンシズ インコーポレイテッド アザインドールｒｏｃｋ阻害剤
IL327381A (en) 2023-09-28 2026-05-01 Graviton Pharmaceuticals B V Treatment for type 1 diabetes using ROCK2 and DYRK1 inhibitors
IL327385A (en) 2023-09-29 2026-05-01 Graviton Pharmaceuticals B V ROCK2 inhibitors in the treatment of obesity
WO2026011129A1 (en) * 2024-07-03 2026-01-08 Avicenna Biosciences, Inc. Azaindole rock inhibitors for the treatment of medical disorders
CN120204259B (zh) * 2025-04-17 2025-11-18 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) Rock2抑制剂及其在制备治疗胆管癌的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7311228B2 (ja) 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
JP7399848B2 (ja) * 2017-09-01 2023-12-18 カドモン コーポレイション，リミティド ライアビリティ カンパニー Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤

Also Published As

Publication number Publication date
WO2023209692A1 (en) 2023-11-02
CN119604496A (zh) 2025-03-11
KR20250019030A (ko) 2025-02-07
US20250289807A1 (en) 2025-09-18
CA3250707A1 (en) 2023-11-02
IL316616A (en) 2024-12-01
AU2023262720A1 (en) 2024-12-12
EP4514466A1 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
CN116249683B (zh) 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
CN111989332B (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
US20250289807A1 (en) Inhibitors of ROCK2
EP3584239B1 (en) O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof
CN117143107A (zh) 1,2-二氢吡啶类衍生物及其制备方法和用途
JP2025539146A (ja) Ｒｏｃｋ２の阻害剤
US10548883B2 (en) Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor
BR112016003247B1 (pt) Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso
RU2641693C2 (ru) Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение
JP2020537669A (ja) ピラゾリル基を含む三環式誘導体、その製造方法及び用途
EP3672950A1 (en) Novel heterocyclic compounds as modulators of mglur7
CN114437116A (zh) 杂环化合物及其制备方法、药物组合物和应用
EP3418277B1 (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
CN112020357B (zh) 含吲唑基的三并环类衍生物的盐及其晶型
JP2025509830A (ja) 血液脳関門を通過するｍｌｌ１－ｗｄｒ５タンパク質間相互作用阻害剤化合物及びそれらの使用
CN114599655B (zh) 咪唑烷酮类化合物及其制备方法与应用
KR102329720B1 (ko) 단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체
JP7110335B2 (ja) プロテインキナーゼ阻害剤として有用なピリドキナゾリン誘導体
CN116535423B (zh) 抑制/诱导降解egfr激酶的化合物及其药物组合物和应用
CN111377906B (zh) 取代的吡嗪化合物及其制备方法和用途
CN121226329A (zh) 一种治疗或预防lrrk2介导的疾病的化合物
CN121824539A (zh) 稠环化合物及其制备方法和应用
KR20250051688A (ko) TGF-β 억제제 화합물 및 그 사용
JP2021523194A (ja) インドリン−１−カルボキサミド化合物、そのための調製方法及びその医学的使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260427